Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! 

China Clinical Trials 2017

Analysis of IND and NDA applications and approvals in China 2011-2017

Download free report on life science investment in China

News & Analysis

China biotech company and industry news and analysis...

Week in Review: Tasly Biopharma Completes Pre-IPO Round at $1.9 Billion Valuation
Tasly Biopharma Raises $84.5 Million in Pre-IPO Round
Haitong Invests in Orig3n, a Boston Genetics/Regenerative Medicine Company
CStone Approved to Start China Clinical Trials of PD-1 Candidate
Merck to Market Xian Janssen's SGLT-2 Diabetes Drug in China
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event

Device China 2018
September 8-9, 2018